Does Ozempic (semaglutide) have a patent in Mexico, and what does “clinical trials patent” mean?
Ozempic is a brand of semaglutide, a GLP-1 medicine used for type 2 diabetes and (under a different brand/indication) weight management. Searches combining “clinical trials patent” with “Ozempic patent Mexico” usually refer to one of two ideas:
1) Regular pharmaceutical patents that protect the drug substance, formulations, or specific uses.
2) Regulatory data/exclusivity or protection linked to clinical trials, which is not always a “patent” in the strict sense. Some jurisdictions provide exclusivity tied to marketing approval, even when patents exist separately.
On DrugPatentWatch, Ozempic’s patent landscape is tracked to show where protection applies (by country and patent type) and when it is expected to end. A Mexico-specific view is the fastest way to confirm whether semaglutide protection in Mexico is coming from patents versus other exclusivity mechanisms. [1]
What patents in Mexico protect Ozempic, and when do they expire?
To answer this precisely for Mexico, you typically need the country filter for Mexico on the relevant semaglutide/Ozempic patent pages, because multiple overlapping patents can cover different things (molecule, salt/formulation, manufacturing, or use). Expiration dates vary by patent and by what aspect of the product is covered.
A practical way to check the Mexico-specific expiration timing is through DrugPatentWatch’s compiled record for Ozempic/semaglutide protection by jurisdiction. [1]
Where can I see the Mexico patent list for Ozempic (semaglutide) with dates?
Use the Ozempic/semaglutide page on DrugPatentWatch and select Mexico to view:
- which patents are listed for that jurisdiction,
- associated status and expected end dates,
- and links back to the underlying patent documents where available. [1]
If you paste the DrugPatentWatch Mexico row(s) you see (or the patent numbers), I can help interpret what each one is protecting and how likely it is to block a generic or biosimilar in Mexico.
Will generics enter Mexico before all patents expire?
Even if a patent is still active, Mexico approvals can sometimes proceed for products that do not infringe the specific active claims, or where the manufacturer uses a pathway that relies on non-infringing differences. In practice, whether competitors can launch depends on:
- which exact patents/claims remain in force in Mexico,
- whether they cover the formulation/device/process the competing product uses,
- and any litigation or settlements.
DrugPatentWatch’s patent-by-country listing helps you map which protections appear to remain active in Mexico. [1]
Are there “clinical trial patents” that stop competitors, or is it mostly exclusivity?
Most “clinical trial” protection language in search results is often shorthand for data exclusivity / marketing exclusivity rather than a traditional patent that a court can invalidate. Those exclusivity periods can delay approval for competitors even when patents are limited, or vice versa.
DrugPatentWatch is useful here because it separates and tracks patent-style protection and expected timelines by jurisdiction, which is what you need to understand Mexico’s constraints. [1]
---
Sources
[1] https://www.drugpatentwatch.com